Myriad reports results from real-world study of patients with depression

Myriad Genetics revealed results from a multi-year, real-world study of nearly 21,000 patients that indicated those with major depressive disorder had reduced healthcare utilization after taking the GeneSight Psychotropic test. The study demonstrated that the percentage of patients with hospitalizations was significantly reduced 180 days after GeneSight testing: 39% relative reduction in psychiatric-related hospitalizations. 29% relative reduction in hospitalizations for any reason. Significant reduction in hospitalizations for patients who were switched to a medication with no or moderate gene-drug interactions. The study found that, among patients who took the GeneSight test, there was a decrease in the proportion of patients who were prescribed medications with significant gene-drug interactions after taking the test: The percentage of patients who were prescribed medications in the significant gene-drug interaction category was reduced from 26.1% to 15.9%. The percentage of patients who were prescribed medications with no gene-drug interactions increased from 27.5% to 47%.